Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by John Kuruvilla
Mocetinostat for Relapsed Classical Hodgkin's Lymphoma: An Open-Label, Single-Arm, Phase 2 Trial
The Lancet Oncology
Oncology
Benefit of Allogeneic Transplantation in Patients Age ≥ 60 Years With Acute Myeloid Leukemia Is Limited to Those in First Complete Remission at Time of Transplant
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Related publications
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin's Lymphoma: An Open-Label Phase 1 Trial
The Lancet
Medicine
Once-Weekly Ofatumumab in Untreated or Relapsed Waldenström's Macroglobulinaemia: An Open-Label, Single-Arm, Phase 2 Study
The Lancet Haematology
Hematology
Sintilimab for Relapsed/Refractory (R/R) Extranodal Nk/T Cell Lymphoma (Enktl): A Multicenter, Single-Arm, Phase 2 Trial (Orient-4)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Meglumine Antimoniate Intralesional Infiltration for Localised Cutaneous Leishmaniasis: A Single Arm, Open Label, Phase II Clinical Trial
Memorias do Instituto Oswaldo Cruz
Medicine
Microbiology
Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-Pd-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
OA10.05 an Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients With Uncommon EGFR Mutation(KCSG-Lu15-09)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Irinotecan–temozolomide With Temsirolimus or Dinutuximab in Children With Refractory or Relapsed Neuroblastoma (COG ANBL1221): An Open-Label, Randomised, Phase 2 Trial
The Lancet Oncology
Oncology
988 an Open-Label Phase 2 Clinical Trial of Topical Remetinostat Gel for Basal Cell Carcinoma
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
Ibrutinib as Initial Therapy for Elderly Patients With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma: An Open-Label, Multicentre, Phase 1b/2 Trial
The Lancet Oncology
Oncology
